Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Go back to Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)| Beam Inc. (NASDAQ: BEAM) | Delayed: 27.48 +0.23 (0.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.25 | 52 Week High | $83.60 | |||
| Open | $27.71 | 52 Week Low | $82.96 | |||
| Day High | $28.35 | P/E | 12.27 | |||
| Day Low | $27.13 | EPS | $2.24 | |||
| Volume | 1,324,259 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 27.48 +0.23 (0.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.25 | 52 Week High | $83.60 | |||
| Open | $27.71 | 52 Week Low | $82.96 | |||
| Day High | $28.35 | P/E | 12.27 | |||
| Day Low | $27.13 | EPS | $2.24 | |||
| Volume | 1,324,259 | |||||
